Corgenix Announces Establishment Of Bio-Terrorism Defense Development Program

DENVER, Jan. 26 /PRNewswire-FirstCall/ -- Corgenix Medical Corporation (BULLETIN BOARD: CONX) today announced establishment of a program to develop a rapid detection system for viral hemorrhagic fevers, a disease category recognized and classified for its risk as potential agents of bio-terrorism. Viral hemorrhagic fevers are included in the high priority "Category A" of biological diseases as defined by the Centers for Disease Control and Prevention (CDC). Along with anthrax, botulism, plague, smallpox and tularemia, viruses causing hemorrhagic fevers have been identified as key targets in the effort to understand and combat potential agents of bio-terrorism.

In commenting about this new initiative in bio-terrorism defense diagnostics, Douglass Simpson, Corgenix President said, "This is a logical growth opportunity for Corgenix in a critical area that needs to be addressed on a national and international level. Through our strategic relationships with industry and academic scientists we have access to some very promising viral technology that we believe will fit nicely with our existing delivery systems for testing and diagnosis. With our collaborators, we expect to move through the research stage towards definitive diagnostic and detection systems, and have recently submitted a significant grant proposal to the National Institute of Health (NIH) for additional funding for this program." Simpson continued, "Bio-Terrorism Defense is a very important issue in this day and age, and we are confident that our collaboration with key industry and academic scientists will show meaningful results in a short period of time. We expect to present our program to the CDC, U.S. Department of Defense, and U.S. Department of Homeland Security, among other important government agencies and interested parties."

About Corgenix Medical Corporation

Corgenix is a leader in the development and manufacturing of anti-Phospholipid test kits, being the first on the market with an FDA cleared assay for anti-Cardiolipin (aCL). The Company is based in metropolitan Denver and is focused on the development of specialized diagnostic kits for immunology disorders, vascular diseases and bone and joint disorders. Corgenix diagnostic products are commercialized for use in clinical laboratories throughout the world. More information is available at Complete copies of the Corgenix Medical Corporation Forms 10-KSB and 10-QSB are available at

Statements in this press release that are not strictly historical facts are "forward looking" statements (identified by the words "believe," "estimate," "project," "expect" or similar expressions) within the meaning of the Private Securities Litigation Reform Act of 1995. These statements inherently involve risks and uncertainties that could cause actual results to differ materially from the forward-looking statements. Factors that would cause or contribute to such differences include, but are not limited to, failure to raise the necessary equity capital, continued acceptance of the Company's products and services in the marketplace, competitive factors, changes in the regulatory environment, and other risks detailed in the Company's periodic report filings with the Securities and Exchange Commission. The statements in this press release are made as of today, based upon information currently known to management, and the company does not undertake any obligation to publicly update or revise any forward-looking statements.

For more information, contact: William Critchfield, CFO: (303) 453-8903;

Corgenix Medical Corporation

CONTACT: William Critchfield, CFO of Corgenix Medical Corporation,+1-303-453-8903,

Back to news